Medivation price target raised to $105 from $97 at Jefferies
Jefferies raised its price target on Medivation (MDVN) to $105 after positive results were reported for Johnson & Johnson's (JNJ) Zytiga. Jefferies said that it thinks Medivation's enzalutamide could match or beat the overall survival results reported for Zytiga and the firm keeps a Buy rating on Medivation shares.